vTv Therapeutics Q4 net loss widens on higher expenses

vTv Therapeutics

10/03/2026 20:10

Overview

US diabetes drug developer's Q4 net loss widened on higher R&D and G&A expenses

Company reported no revenue for Q4 2025

Cash position strengthened by $20 mln upfront payment from Newsoara and private placement financing

Outlook

vTv expects to complete CATT1 Phase 3 trial enrollment in Q3 2026

Company says funding runway extends well past anticipated CATT1 Phase 3 topline readout

Result Drivers

HIGHER R&D SPENDING - Co said increased R&D expenses were mainly due to higher spending on cadisegliatin clinical studies

HIGHER G&A COSTS - Co attributed increased G&A expenses to higher payroll, legal, and share-based costs

The Company’s cash position as of December 31, 2025, was $88.9 million compared to $36.7 million as of December 31, 2024

Company press release: ID:nGNX8Hff61

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.58
Q4 Operating Expenses
$7.89 mln
Q4 Operating Income
-$7.89 mln
Q4 Pretax Profit
-$7.14 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for vTv Therapeutics Inc is $49.00, about 34.2% above its March 9 closing price of $36.52

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)